Pharmacokinetics of gadoversetamide injection, a gadolinium-based contrast agent, in pediatric patients

Magnetic Resonance Imaging

Volumn 27, Issue 4, 2009, Pages 512-518

  Wible Jr , James H ^a   Tata, Prasad N V ^a   Napoli, Alicia M ^a   Lowe, Lisa H ^b,c   Kearns, Gregory L ^b,d  

^a MEDTRONIC INC   (United States)

^b CHILDREN S MERCY HOSPITAL   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^d UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

Gadolinium; Gadoversetamide; MRI Contrast agents; OptiMARK; Pediatric patients; Pharmacokinetics

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM; GADOVERSETAMIDE;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY MASS; BODY SIZE; CENTRAL NERVOUS SYSTEM; CHILD; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; GROUPS BY AGE; HUMAN; INJECTION; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PEDIATRICS; PRIORITY JOURNAL; SEX; SURFACE PROPERTY; URINALYSIS;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CONTRAST MEDIA; FEMALE; HUMANS; INJECTIONS, INTRA-ARTERIAL; MAGNETIC RESONANCE IMAGING; MALE; METABOLIC CLEARANCE RATE; ORGANOMETALLIC COMPOUNDS;

EID: 63349083236     PISSN: 0730725X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mri.2008.08.002     Document Type: Article

References (24)

1. Desreux J.F., and Gilsoul D. Chemical synthesis of paramagnetic complexes. In: Thomsen H.S., Muller R.N., and Mattrey R.F. (Eds). Trends in contrast imaging (1999), Springer-Verlag, Berlin, Germany 161-169
2. Powers T.A., Partain C.L., Kessler R.M., et al. Central nervous system lesions in pediatric patients: Gd-DTPA-enhanced MR imaging. Radiology. 169 (1988) 723-726
3. Lundby B., Gordon P., and Hugo F. MRI in children given gadodiamide injection: safety and efficacy in CNS and body indications. Eur J Radiol 23 (1996) 190-196
4. Ball Jr. W.S., Nadel S.N., Zimmerman R.A., Byrd S.E., Dietrich R.B., Prenger E.C., et al. Phase III multicenter clinical investigation to determine the safety and efficacy of gadoteridol in children suspected of having neurologic disease. Radiology 186 (1993) 769-774
5. Grossman R.I., Rubin D.L., Hunter G., et al. Magnetic resonance imaging in patients with central nervous system pathology: a comparison of OptiMARK (Gd-DTPA-BMEA) and Magnevist (Gd-DTPA). Invest Radiol 35 (2000) 412-419
6. Lowe L.H., Kearns G.L., and Wible Jr. J.H. The safety and efficacy of neuroimaging with gadoversetamide injection in pediatric patients. Curr Med Res Opin 22 (2006) 2515-2524
7. FDA Guidance for Industry, Bioanalytical Method Validation 2001.
8. DuBois D., and DuBois E.F. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 16 (1916) 863-871
9. Swan S.K., Baker J.F., Free R., et al. Pharmacokinetics, safety, and tolerability of gadoversetamide injection (OptiMARK) in subjects with central nervous system or liver pathology and varying degrees of renal function. J Magn Reson Imaging 9 (1999) 317-321
10. Shepherd J.T., and Vanhoutte P.M. The human cardiovascular system: facts and concepts (1979), Raven Press, New York (NY) 328
11. Baker J.F., Kratz L.C., Stevens G.R., and Wible Jr. J.H. Pharmacokinetics and safety of the MRI contrast agent gadoversetamide injection (OptiMARK) in healthy pediatric subjects. Invest Radiol 39 (2004) 334-339
12. Chumlea W.C., Schubert C.M., Reo N.V., Sun S.S., and Siervogel R.M. Total body water volume for white children and adolescents and anthropometric prediction equations: the Fels Longitudinal Study. Kidney Int 68 (2005) 2317-2322
13. Cheek D.B. Observations on total body chloride in children. Pediatrics 14 (1954) 5-10
14. Kearns G.L., Abdel-Rahman S.M., Alander S.W., Blowey D.L., Leeder J.S., and Kauffman R.E. Developmental pharmacology - drug disposition, action and therapy in infants and children. N Engl J Med 349 (2003) 1157-1167
15. Papadopoulou Z.L., Tina L.U., Sandler P., Jose P.A., and Calcagno P.L. Size and function of the kidneys. In: Johnson T.R., Moore W.M., and Jeffries J.E. (Eds). Children are different: developmental physiology (1978), Ross Laboratories, Columbus (Ohio) 97-103
16. Spitzer A., and Chevalier R.L. The developing kidney and the process of growth. In: Seldin D.W., and Giebisch G. (Eds). The kidney: physiology and pathophysiology (1992), Raven Press, New York (NY) 820-883
17. Levi M., and Rowe J.W. Renal function and dysfunction in aging. In: Seldin D.W., and Giebisch G. (Eds). The kidney: physiology and pathophysiology (1992), Raven Press, New York (NY) 3433-3456
18. U.S. Food and Drug Administration. FDA news: FDA requests boxed warning for contrast agents used to improve MRI images. Food and Drug Administration Web site. http://www.fda.gov/bbs/topics/NEWS/2007/NEW01638.html [Published May 23, 2007]
19. Cowper S.E. Nephrogenic systemic fibrosis: a review and exploration of the role of gadolinium. Adv Dermatol 23 (2007) 31-154
20. Joffe P., Thomsen H.S., and Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 5 (1998) 491-502
21. Schuhmann-Giampieri G., and Krestin G. Pharmacokinetics of Gd-DTPA in patients with chronic renal failure. Invest Radiol 26 (1991) 975-979
22. McLachlan S.J., Eaton S., and De Simone D.N. Pharmacokinetic behavior of gadoteridol injection. Invest Radiol 27 Suppl 1 (1992) S12-S15
23. Brown J.J., Hynes M.R., and Wible Jr. J.H. Measurement of serum calcium concentration after administration of four gadolinium-based contrast agents to human volunteers. Am J Roentgenol 189 (2007) 1539-1544
24. Davies B.E., Kozlowski K., Parker J.R., Krinsky L., Hutman H., and LaFrance N. The pharmacokinetics of MultiHance in pediatric subjects, a population approach. Clin Pharmacol Ther 65 (1999) 139